These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
416 related articles for article (PubMed ID: 11156246)
1. The prognostic value of angiogenesis factor expression for predicting recurrence and metastasis of bladder cancer after neoadjuvant chemotherapy and radical cystectomy. Inoue K; Slaton JW; Karashima T; Yoshikawa C; Shuin T; Sweeney P; Millikan R; Dinney CP Clin Cancer Res; 2000 Dec; 6(12):4866-73. PubMed ID: 11156246 [TBL] [Abstract][Full Text] [Related]
2. The prognostic value of angiogenesis and metastasis-related genes for progression of transitional cell carcinoma of the renal pelvis and ureter. Inoue K; Kamada M; Slaton JW; Fukata S; Yoshikawa C; Tamboli P; Dinney CP; Shuin T Clin Cancer Res; 2002 Jun; 8(6):1863-70. PubMed ID: 12060629 [TBL] [Abstract][Full Text] [Related]
3. Treatment with low-dose interferon-alpha restores the balance between matrix metalloproteinase-9 and E-cadherin expression in human transitional cell carcinoma of the bladder. Slaton JW; Karashima T; Perrotte P; Inoue K; Kim SJ; Izawa J; Kedar D; McConkey DJ; Millikan R; Sweeney P; Yoshikawa C; Shuin T; Dinney CP Clin Cancer Res; 2001 Sep; 7(9):2840-53. PubMed ID: 11555602 [TBL] [Abstract][Full Text] [Related]
4. Vascular endothelial growth factor-C (VEGF-C) expression predicts lymph node metastasis of transitional cell carcinoma of the bladder. Suzuki K; Morita T; Tokue A Int J Urol; 2005 Feb; 12(2):152-8. PubMed ID: 15733109 [TBL] [Abstract][Full Text] [Related]
5. The effect of cystectomy, and perioperative methotrexate, vinblastine, doxorubicin and cisplatin chemotherapy on the risk and pattern of relapse in patients with muscle invasive bladder cancer. Ennis RD; Petrylak DP; Singh P; Bagiella E; O'Toole KM; Benson MC; Olsson CA J Urol; 2000 May; 163(5):1413-8. PubMed ID: 10751847 [TBL] [Abstract][Full Text] [Related]
6. Adjuvant polychemotherapy of nonorgan-confined bladder cancer after radical cystectomy revisited: long-term results of a controlled prospective study and further clinical experience. Stöckle M; Meyenburg W; Wellek S; Voges GE; Rossmann M; Gertenbach U; Thüroff JW; Huber C; Hohenfellner R J Urol; 1995 Jan; 153(1):47-52. PubMed ID: 7966789 [TBL] [Abstract][Full Text] [Related]
7. Primary cisplatin, methotrexate and vinblastine aiming at bladder preservation in invasive bladder cancer: multivariate analysis on prognostic factors. Angulo JC; Sanchez-Chapado M; Lopez JI; Flores N J Urol; 1996 Jun; 155(6):1897-902. PubMed ID: 8618282 [TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of adjuvant cisplatin-based combination chemotherapy following radical cystectomy in patients with invasive bladder cancer. Muramaki M; Miyake H; Kurahashi T; Takenaka A; Inoue TA; Fujisawa M Int J Urol; 2008 Apr; 15(4):314-8. PubMed ID: 18380818 [TBL] [Abstract][Full Text] [Related]
9. Adjuvant chemotherapy for deep muscle-invasive transitional cell bladder carcinoma - a practice guideline. Segal R; Winquist E; Lukka H; Chin JL; Brundage M; Markman BR; Can J Urol; 2002 Oct; 9(5):1625-33. PubMed ID: 12431323 [TBL] [Abstract][Full Text] [Related]
10. Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin (AMVAC) as neoadjuvant chemotherapy for patients with muscle-invasive transitional cell carcinoma of the bladder. Blick C; Hall P; Pwint T; Al-Terkait F; Crew J; Powles T; Macaulay V; Munro N; Douglas D; Kilbey N; Protheroe A; Chester JD Cancer; 2012 Aug; 118(16):3920-7. PubMed ID: 22614698 [TBL] [Abstract][Full Text] [Related]
11. [The role of M-VAC polychemotherapy in the treatment of advanced urothelial carcinoma of the bladder]. Stöckle M; Meyenburg W; Wellek S; Voges G; Gertenbach U; Thüroff JW; Huber C; Hohenfellner R Ann Urol (Paris); 1993; 27(1):51-7. PubMed ID: 7682388 [TBL] [Abstract][Full Text] [Related]
12. [Neoadjuvant and adjuvant chemotherapy of bladder cancer]. Kuroda M; Kotake T Gan To Kagaku Ryoho; 1994 Oct; 21 Suppl 3():362-9. PubMed ID: 7986116 [TBL] [Abstract][Full Text] [Related]
13. [Vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) expression in superficial transitional cell bladder carcinoma]. Guo ZH; Mei H; Huang J; Li SY Ai Zheng; 2003 Mar; 22(3):307-9. PubMed ID: 12654193 [TBL] [Abstract][Full Text] [Related]
14. Proton beam therapy for invasive bladder cancer: a prospective study of bladder-preserving therapy with combined radiotherapy and intra-arterial chemotherapy. Hata M; Miyanaga N; Tokuuye K; Saida Y; Ohara K; Sugahara S; Kagei K; Igaki H; Hashimoto T; Hattori K; Shimazui T; Akaza H; Akine Y Int J Radiat Oncol Biol Phys; 2006 Apr; 64(5):1371-9. PubMed ID: 16580495 [TBL] [Abstract][Full Text] [Related]
15. [Neoadjuvant chemotherapy (M-VAC) in invasive cancer of the bladder. Our experience]. González Enguita C; Caro Cebrián C; Roncalés Badal A; Gil Sanz MJ; Martínez Bengoechea J; Rioja Sanz LA Arch Esp Urol; 1990; 43 Suppl 2():197-204. PubMed ID: 2096779 [TBL] [Abstract][Full Text] [Related]
16. Can patient selection for bladder preservation be based on response to chemotherapy? Sternberg CN; Pansadoro V; Calabrò F; Schnetzer S; Giannarelli D; Emiliozzi P; De Paula F; Scarpone P; De Carli P; Pizzo M; Platania A; Amini M Cancer; 2003 Apr; 97(7):1644-52. PubMed ID: 12655521 [TBL] [Abstract][Full Text] [Related]
17. Vascular endothelial growth factor-C expression in bladder transitional cell cancer and its relationship to lymph node metastasis. Zu X; Tang Z; Li Y; Gao N; Ding J; Qi L BJU Int; 2006 Nov; 98(5):1090-3. PubMed ID: 17034609 [TBL] [Abstract][Full Text] [Related]
18. Expression of vascular endothelial growth factor (VEGF) and its receptors (Flt-1 and Flk-1) in esophageal squamous cell carcinoma. Kato H; Yoshikawa M; Miyazaki T; Nakajima M; Fukai Y; Masuda N; Fukuchi M; Manda R; Tsukada K; Kuwano H Anticancer Res; 2002; 22(6C):3977-84. PubMed ID: 12553021 [TBL] [Abstract][Full Text] [Related]